Get started
Author

B. Gueron

Observed names: B Gueron, B Guéron, Beatrice Gueron, Béatrice Guéron, Gueron, Beatrice
Observed institutions: Janssen (Belgium), Cemka-Eval (France), Bristol-Myers Squibb (France), Pfizer (France), Recordati (France), Recordati Rare Diseases, Inc. (United States)
ORCID: 0009-0007-0832-9926
Observed ORCID: 0009-0007-0832-9926
OpenAlex ID: A5089495687
Update on asthma control in five European countries: results of a 2008 survey
2010 · P. Demoly, B. Gueron, et al. · European Respiratory Review · 148
PDF
Studying the Hurdles of Insulin Prescription (SHIP©): development, scoring and initial validation of a new self-administered questionnaire
2007 · Luc Martinez, Silla M Consoli, et al. · Health and Quality of Life Outcomes · 36
PDF
Costs of cardiovascular events of diabetic patients in the French hospitals
2007 · X. Colin, A. Lafuma, et al. · Diabetes & Metabolism · 13
Prise en compte de l’effet propre du diabète de type II sur la mesure du coût de ses principales complications
2006 · J.-P. Marissal, B. Gueron, et al. · Revue d Épidémiologie et de Santé Publique · 6
Matching-Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing’s Syndrome
2025 · Conor Hickey, Beatrice Gueron, et al. · Advances in Therapy · 5
Cost-Effectiveness Of Ipilimumab In Previously Treated Patients For Advanced Melanoma In Portugal
2013 · M. Radford, P. Cortes, et al. · Value in Health · 5
PDF
Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden
2014 · V. Barzey, Y. Asukai, et al. · Value in Health · 4
PDF
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service
2017 · Kirsten Westerhout, Walter Bouwmeester, et al. · ClinicoEconomics and Outcomes Research · 3
PDF
3115 Real-world treatment patterns among patients with advanced non-small cell lung cancer in Europe: Evidence from a retrospective chart review in France, Germany, Italy and Spain
2015 · C. Solem, J. Penrod, et al. · European Journal of Cancer · 2
Patient Count Projections for Advanced Melanoma by Line of Therapy and Other Clinical Characteristics in EU Countries: Results from The UK, Germany, France, Italy and Spain (EU-5)
2014 · B. Gueron, J.K. Kish, et al. · Value in Health · 2
Extrapolating Survival in a Heterogeneous Patient Population with Metastatic Melanoma; A Case Study of Integrating Statistical and Clinical Consideration
2013 · I.M. Majer, B. Gueron, et al. · Value in Health · 2
PDF
An Exploratory Analysis of the Association Between EORTC-QLQ C30 Domains and Progression Free/Overall Survival in Advanced Melanoma After 12 Weeks of Treatment on Ipilimumab Compared to Gp100 in a Phase III Clinical Trial
2013 · D. Lee, B. Harvey, et al. · Value in Health · 2
PDF
Pdb37 Scoring and Psychometric Validation of a Scale for Diabetic Patient Profiling Based on Patient Attitude Towards Insulin
2006 · B Arnould, V Bosch, et al. · Value in Health · 2
PDF
Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials
2026 · John Newell‐Price, Beverly M. K. Biller, et al. · Clinical Endocrinology · 1
Changes in the quality of life of advanced melanoma patients after 12 weeks of treatment with ipilimumab compared to gp100 in a phase III clinical trial.
2013 · Becca Harvey, Dawn Lee, et al. · Journal of Clinical Oncology · 1
Prs9 Quality of Life and Economic Impact of Asthma Control in France and Spain. First Results of the Eu-coast Study
2010 · C Chouaid, Corbella E Calvo, et al. · Value in Health · 1
Prs31 a Survey of the Burden of Allergic Rhinitis in Europe
2008 · B Gueron, GW Canonica, et al. · Value in Health · 1
PDF
Cost−effectiveness of pasireotide as second−line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System
2026 · Vania dos Santos Nunes Nogueira, Grzegorz Binowski, et al. · Frontiers in Endocrinology
PDF
P306 - ECE_1924 - Impact of osilodrostat on health-related quality of life in Cushing's disease: analysis of patient-reported outcomes from the Phase III LINC 3 and LINC 4 studies
2026 · John Newell-Price, Beverly M K Biller, et al. · European Journal of Endocrinology
PDF
EP1075 - ECE_1915 - Quality-of-life improvements in patients with Cushing's syndrome: results from an ad hoc analysis of new osilodrostat users in a prospective, non-interventional study (LINC 6)
2026 · Stéphanie Espiard, Jérôme Bertherat, et al. · European Journal of Endocrinology
Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment
2026 · Aleksandra Gilis-Januszewska, Małgorzata Bronikowska, et al. · Journal of Medical Economics
PDF
Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment
2026 · Gilis-Januszewska, Aleksandra, Bronikowska, Małgorzata, et al. · Figshare
CO150 Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence
2025 · Grzegorz Binowski, KOSSI Dédé Sika, et al. · Value in Health
PCR91 Health-Related Quality of Life of Patients With Cushing’s Disease Treated With Osilodrostat: Mixed-Effects Regression Analysis
2024 · G. Binowski, B. Gueron, et al. · Value in Health
PDF
Comparative efficacy and safety of osilodrostat vs metyrapone for the treatment of Cushing's syndrome - a matching-adjusted indirect comparison using LINC-3 and LINC-4
2024 · Rosario Pivonello, Beatrice Gueron, et al. · Endocrine Abstracts
Works count: 33
Citation count: 234
H-index: 5
I10-index: 3
Year
Topic
Type